Fate Therapeutics and Mirum Pharmaceuticals List on Nasdaq
1 report, 1 independent
Updated Oct 5
AI-generated briefing. Brind wrote this from the reports listed below and has updated it as the story developed. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Fate Therapeutics and Mirum Pharmaceuticals successfully listed on the Nasdaq stock exchange on October 5, 2026. Both companies are healthcare firms.
From tickerreport.com
Why it matters
Reports compare the two companies' financial profiles, noting that Mirum Pharmaceuticals has higher revenue and earnings per share while trading at a lower price-to-earnings ratio. Analysts suggest Fate Therapeutics has a higher potential upside, though its stock is significantly more volatile than Mirum Pharmaceuticals.
From tickerreport.com
Who's involved
- Fate TherapeuticsClinical-stage biopharmaceutical company listed on Nasdaq
- Mirum PharmaceuticalsBiopharmaceutical company listed on Nasdaq
- NasdaqAmerican stock exchange where both companies trade
Keep exploring
The entities involved
-
Fate Therapeutics
a clinical-stage biopharmaceutical company in San Diego, United States
Nothing else this week.
-
Mirum Pharmaceuticals
biopharmaceutical company
Nothing else this week.
-
Nasdaq
American fully electronic stock exchange
Related events
- Praxis Precision Medicines and Relay Therapeutics were listed on the Nasdaq stock exchange on October 1, 2026.
- BioMarin Pharmaceutical and CollPlant Biotechnologies were listed on Nasdaq and are being compared as healthcare companies.
- Mirum Pharmaceuticals and United Therapeutics are being compared as healthcare companies.
- INmune Bio Inc. listed its shares on the stock exchange on July 9, 2026.
- Fate Therapeutics and Applied Therapeutics are both identified as small-cap healthcare companies.